NASDAQ:CNTX Context Therapeutics (CNTX) Stock Price, News & Analysis $2.42 +0.03 (+1.09%) As of 12:09 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Context Therapeutics Stock (NASDAQ:CNTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Context Therapeutics alerts:Sign Up Key Stats Today's Range$2.38▼$2.4950-Day Range$2.25▼$3.3652-Week Range$0.49▼$3.62Volume90,885 shsAverage Volume1.35 million shsMarket Capitalization$221.98 millionP/E RatioN/ADividend YieldN/APrice Target$6.60Consensus RatingModerate Buy Company Overview Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors. With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies. The company’s development strategy integrates translational science, rigorous patient selection and adaptive trial design, aiming to streamline pathways to regulatory review. Through these efforts, Context Therapeutics seeks to establish proof of concept across multiple indications before pursuing broader commercialization alliances. Headquartered in the United States, Context Therapeutics conducts its clinical research primarily in North America while laying the groundwork for potential global expansion. The company’s leadership team combines industry veterans in drug development with specialists in oncology and translational medicine. Together, they guide Context Therapeutics as it advances novel candidates through clinical milestones, with the goal of delivering targeted treatment options to patients with high unmet medical need.AI Generated. May Contain Errors. Read More Context Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreCNTX MarketRank™: Context Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 241st out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingContext Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialContext Therapeutics has a consensus price target of $6.60, representing about 170.2% upside from its current price of $2.44.Amount of Analyst CoverageContext Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Context Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Context Therapeutics are expected to decrease in the coming year, from ($0.35) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Context Therapeutics is -5.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Context Therapeutics is -5.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContext Therapeutics has a P/B Ratio of 3.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.03% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 0.78, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Context Therapeutics has recently increased by 4.05%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldContext Therapeutics does not currently pay a dividend.Dividend GrowthContext Therapeutics does not have a long track record of dividend growth. News and Social Media4.4 / 5News Sentiment0.99 News SentimentContext Therapeutics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Context Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for CNTX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows5 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Context Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.80% of the stock of Context Therapeutics is held by insiders.Percentage Held by Institutions14.03% of the stock of Context Therapeutics is held by institutions.Read more about Context Therapeutics' insider trading history. Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTX Stock News HeadlinesContext Therapeutics Reports First Quarter 2026 Operating and Financial ResultsMay 6, 2026 | globenewswire.comContrasting Context Therapeutics (NASDAQ:CNTX) & Telomir Pharmaceuticals (NASDAQ:TELO)May 6, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 12 at 1:00 AM | InvestorPlace (Ad)Context Therapeutics (CNTX) Expected to Announce Quarterly Earnings on WednesdayMay 4, 2026 | americanbankingnews.comPositive Signs As Multiple Insiders Buy Context Therapeutics StockApril 28, 2026 | finance.yahoo.comContext Therapeutics rises on FDA fast track status for lead assetApril 2, 2026 | seekingalpha.comContext Therapeutics Receives FDA Fast Track Designation for CTIM-76 in Platinum-Resistant Ovarian CancerApril 2, 2026 | quiverquant.comQContext Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian CancerApril 2, 2026 | globenewswire.comSee More Headlines CNTX Stock Analysis - Frequently Asked Questions How have CNTX shares performed this year? Context Therapeutics' stock was trading at $1.47 at the beginning of 2026. Since then, CNTX shares have increased by 66.2% and is now trading at $2.4430. How were Context Therapeutics' earnings last quarter? Context Therapeutics Inc. (NASDAQ:CNTX) issued its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.03. When did Context Therapeutics IPO? Context Therapeutics (CNTX) raised $25 million in an initial public offering (IPO) on Tuesday, October 19th 2021. The company issued 5,000,000 shares at $5.00 per share. Who are Context Therapeutics' major shareholders? Top institutional shareholders of Context Therapeutics include Sanctuary Advisors LLC (0.02%). Insiders that own company stock include Martin A Lehr, Jennifer Lynn Minai-Azary and Alex C Levit. View institutional ownership trends. How do I buy shares of Context Therapeutics? Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Context Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Context Therapeutics investors own include NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Celestica (CLS). Company Calendar Last Earnings5/06/2026Today5/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CNTX's financial health is in the Green zone, according to TradeSmith. CNTX has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTX CIK1842952 Webwww.contexttherapeutics.com Phone267-225-7416FaxN/AEmployees7Year Founded2015Price Target and Rating Average Price Target for Context Therapeutics$6.60 High Price Target$9.00 Low Price Target$5.00 Potential Upside/Downside+173.2%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-59.95% Return on Assets-54.78% Debt Debt-to-Equity RatioN/A Current Ratio8.96 Quick Ratio8.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book3.66Miscellaneous Outstanding Shares91,880,000Free Float87,469,000Market Cap$221.98 million OptionableNot Optionable Beta1.57 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CNTX) was last updated on 5/12/2026 by MarketBeat.com Staff. From Our PartnersTrump is positioned. Elon lights the fuse.On Thursday, the Senate Banking Committee votes on the CLARITY Act. A bill that would create the first real le...Crypto 101 Media | SponsoredIran broke the petrodollar…For 50 years, every barrel of oil settled in dollars - that rule is what made the dollar the world's reserve c...Golden Portfolio | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredBSEM: From OTC to Nasdaq Contender!BioStem Technologies (OTC: BSEM) has posted seven consecutive profitable quarters and just released audited fi...Huge Alerts | SponsoredIf You Have $50k+ on Coinbase, This Will Ruin Your DayIn 2009, Greece's debt-to-GDP ratio hit 130%. Within 24 months... Pensions were slashed 40% overnight. Bank ac...Decentralized Masters | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
